Opendata, web and dolomites

SN-marker SIGNED

Secretoneurin (SN): the first blood biomarker to accurately stratify mortality risk in patients with cardiac arrhythmia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SN-marker project word cloud

Explore the words cloud of the SN-marker project. It provides you a very rough idea of what is the project "SN-marker" about.

disease    prescribe    134m    victims    ivd    unmatched    saved    eligible    35    diverted    surgery    threatening    rights    defibrillator    levels    kit    sn    trl6    keeping    alone    rightly    frequent    vitro    assay    icds    activated    market    24    ventricle    arrhythmia    accurate    added    unknowingly    survival    q3    lvef    detect    reached    provides    life    cvd    never    difficult    months    biomarker    data    ventricular    10    stratify    caused    first    34    diagnostic    time    cardinor    killer    accurately    67    patients    death    categories    cardioverter    2018    left    20k    icd    ecg    chain    scd    cardiovascular    prognostic    select    arrhythmias    implantable    patient    echocardiogram    sudden    biomarkers    platforms    least    cardiologists    pinpoint    mechanisms    helps    info    half    worldwide    capacity    2020    deaths    lt    heart    ejection    secretoneurin    decision    elisa    diagnosis    risk    normal    ipr    51    overtreatment    blood    urgently    sales    correlation    cardiac    hf   

Project "SN-marker" data sheet

The following table provides information about the project.

Coordinator
CARDINOR AS 

Organization address
address: GAUSTADALLEEN 21
city: OSLO
postcode: 349
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARDINOR AS NO (OSLO) coordinator 50˙000.00

Map

 Project objective

Cardiovascular disease (CVD) is the no. 1 killer worldwide. At least half of CVD deaths is caused by ventricular arrhythmias that lead to sudden cardiac death (SCD). The diagnosis of arrhythmias is difficult but crucial for accurate decision-making and patient survival, being more frequent and carrying greater risk in heart failure (HF) patients. When managing HF patients, cardiologists currently prescribe an ECG (which may detect an arrhythmia) and an echocardiogram to measure the blood ejection from the left ventricle (LVEF), since there is a correlation between LVEF and risk of ventricular arrhythmias. If LVEF is < 35%, the patient is eligible for implantable cardioverter-defibrillator (ICD) surgery, which costs at least 20K€. Still, around 51 % of victims of SCD have normal LVEF. In addition, 67% of all implemented ICDs are never activated because those patients were (unknowingly) at low-risk for arrhythmias, which represents a 1.34 B€ overtreatment cost/year in the EU alone. Cardiologists urgently need an accurate biomarker that helps to better stratify patients’ risk for life-threatening arrhythmia. Existing cardiac biomarkers do not provide that info, keeping under or overtreatment. CardiNor has IPR rights and is bringing to market a new in vitro diagnostic (IVD) test to measure blood levels of Secretoneurin (SN), a new biomarker that provides unmatched insight into the mechanisms of arrhythmia, with a prognostic capacity to accurately stratify the patients into risk categories. With SN data, cardiologists will be able to rightly pinpoint high-risk patients and select those patients to ICD surgery. For every 10% of ICD-eligible patients that are diverted from surgery more than 134M€ are saved every year. First sales will be in 2020 as an ELISA kit and over time added to other IVD platforms to increase exploitation potential. CardiNor and its value chain partners have been working together on the SN assay for 24 months, having reached TRL6 in Q3 2018.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SN-MARKER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SN-MARKER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MealHero (2019)

Automated cooking for tasty and healthy meals in a convenient way

Read More  

GUARDIAN (2020)

Eco-friendly smart doors for non-residential building fire protection

Read More  

BEMYEYES (2019)

Specialized Help from Be My Eyes – harnessing technology to connect companies directly with their blind and visually impaired users

Read More